Details
Stereochemistry | RACEMIC |
Molecular Formula | C17H20N2S.C14H10O4 |
Molecular Weight | 526.646 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
Stereo Comments | C17 H20 N2 S |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC=CC=C1C(=O)C2=CC=C(O)C=C2.CC(CN3C4=C(SC5=C3C=CC=C5)C=CC=C4)N(C)C
InChI
InChIKey=WCYMACWVZQIWLM-UHFFFAOYSA-N
InChI=1S/C17H20N2S.C14H10O4/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19;15-10-7-5-9(6-8-10)13(16)11-3-1-2-4-12(11)14(17)18/h4-11,13H,12H2,1-3H3;1-8,15H,(H,17,18)
Promethazine is a phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. Promethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12657913 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Preventing | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
|||
Primary | PROMETHAZINE HYDROCHLORIDE Approved UsePromethazine HCl Oral Solution is useful for: perennial and seasonal allergic rhinitis. Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. Launch Date2010 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.28 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
21.84 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
48.26 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
19.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.04 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11511 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14466 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
146.62 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
180.14 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
627.13 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6743785/ |
50 mg single, intramuscular dose: 50 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
146 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
361 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
256 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6849764/ |
12.5 mg single, intravenous dose: 12.5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PROMETHAZINE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
17.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
25 mg single, rectal dose: 25 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
18.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
17.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10965395/ |
50 mg single, rectal dose: 50 mg route of administration: Rectal experiment type: SINGLE co-administered: |
PROMETHAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Disc. AE: Sinus tachycardia, Consciousness decreased... AEs leading to discontinuation/dose reduction: Sinus tachycardia Sources: Page: p.242Consciousness decreased Agitation Confusion Disorientation Visual hallucinations Delirium |
160 mg single, intramuscular Highest studied dose Dose: 160 mg Route: intramuscular Route: single Dose: 160 mg Sources: Page: p.199 |
healthy, 21.4±1.7 n = 6 Health Status: healthy Age Group: 21.4±1.7 Sex: M+F Population Size: 6 Sources: Page: p.199 |
|
120 mg single, intramuscular Higher than recommended Dose: 120 mg Route: intramuscular Route: single Dose: 120 mg Sources: Page: p.199 |
healthy, 22.7±2.31 n = 10 Health Status: healthy Age Group: 22.7±2.31 Sex: M+F Population Size: 10 Sources: Page: p.199 |
|
80 mg 1 times / day multiple, intramuscular Highest studied dose Dose: 80 mg, 1 times / day Route: intramuscular Route: multiple Dose: 80 mg, 1 times / day Sources: Page: p.199 |
healthy, 24.2±1.17 n = 10 Health Status: healthy Age Group: 24.2±1.17 Sex: M+F Population Size: 10 Sources: Page: p.199 |
|
50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Disc. AE: Respiratory depression, Irritation skin... AEs leading to discontinuation/dose reduction: Respiratory depression (grade 5) Sources: Page: p.1Irritation skin (severe) Pain Thrombophlebitis |
50 mg single, oral (max) Recommended Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: Page: p.2, 3 |
unhealthy Health Status: unhealthy Condition: Perennial and seasonal allergic rhinitis|Vasomotor rhinitis|Allergic conjunctivitis|Allergic urticaria|Dermographism|Anaphylactic reactions|Motion sickness|Sedation Sources: Page: p.2, 3 |
Disc. AE: Respiratory depression... AEs leading to discontinuation/dose reduction: Respiratory depression (grade 5) Sources: Page: p.2, 3 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agitation | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Confusion | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Consciousness decreased | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Delirium | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Disorientation | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Sinus tachycardia | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Visual hallucinations | Disc. AE | 1150 mg single, oral Overdose Dose: 1150 mg Route: oral Route: single Dose: 1150 mg Co-administed with:: cyproheptadine, p.o(200 mg, single) Sources: Page: p.242 |
unhealthy, 14 n = 1 Health Status: unhealthy Condition: Depression Age Group: 14 Sex: F Population Size: 1 Sources: Page: p.242 |
Pain | Disc. AE | 50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Thrombophlebitis | Disc. AE | 50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Respiratory depression | grade 5 Disc. AE |
50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Irritation skin | severe Disc. AE |
50 mg single, intramuscular|intravenous (max) Recommended Dose: 50 mg Route: intramuscular|intravenous Route: single Dose: 50 mg Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Allergic Conditions|Nausea and Vomiting|Sedation Sources: Page: p.1 |
Respiratory depression | grade 5 Disc. AE |
50 mg single, oral (max) Recommended Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: Page: p.2, 3 |
unhealthy Health Status: unhealthy Condition: Perennial and seasonal allergic rhinitis|Vasomotor rhinitis|Allergic conjunctivitis|Allergic urticaria|Dermographism|Anaphylactic reactions|Motion sickness|Sedation Sources: Page: p.2, 3 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 32 uM] | ||||
yes [Inhibition 88 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Neuroleptic malignant syndrome due to promethazine. | 1999 Oct |
|
[Evaluation and treatment of hyperemesis gravidarum]. | 2001 Dec |
|
Mechanistic appraisal of the charge-transfer complexes of promethazine with chloranil: a modelling approach. | 2001 Jun |
|
The use of on-line and off-line chromatographic extraction techniques coupled with mass spectrometry for support of in vivo and in vitro assays in drug discovery. | 2001 Nov |
|
Codeine ingestion and apparent life-threatening event in a neonate. | 2001 Oct |
|
Treating dyspnea in a patient with advanced chronic obstructive pulmonary disease. | 2001 Sep |
|
Enantioseparation of phenothiazines in capillary zone electrophoresis using cyclodextrins as chiral selectors. | 2001 Sep 28 |
|
Comparing the safety, efficacy and recovery of intranasal midazolam vs. oral chloral hydrate and promethazine. | 2001 Sep-Oct |
|
[Suicidal attempts with old (currently unused) drug]. | 2002 |
|
Antiallergic anti-inflammatory effects of H1-antihistamines in humans. | 2002 |
|
Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study. | 2002 |
|
Investigation of the effect of tablet surface area/volume on drug release from hydroxypropylmethylcellulose controlled-release matrix tablets. | 2002 Apr |
|
Toxicity of ethacrynic acid in isolated rat hepatocytes. | 2002 Apr |
|
Study of the stability of promethazine enantiomers by liquid chromatography using a vancomycin-bonded chiral stationary phase. | 2002 Apr 25 |
|
A systematic approach to the management of postoperative nausea and vomiting. | 2002 Dec |
|
Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes. | 2002 Feb |
|
Low-molecular-weight chiral cation exchangers: novel chiral stationary phases and their application for enantioseparation of chiral bases by nonaqueous capillary electrochromatography. | 2002 Feb |
|
Extractive-spectrophotometric determination of some phenothiazines with dipicrylamine and picric acid. | 2002 Jan 1 |
|
Central effects of cinnarizine: restricted use in aircrew. | 2002 Jun |
|
Treatment patterns of isolated benign headache in US emergency departments. | 2002 Mar |
|
Nanoparticles in plant extracts: influence of drugs on the formation of nanoparticles and precipitates in black tea infusions. | 2002 Mar |
|
Simultaneous determination of promethazine, chlorpromazine, and perphenazine by multivariate calibration methods and derivative spectrophotometry. | 2002 May-Jun |
|
Preparation, characterization and taste-masking properties of polyvinylacetal diethylaminoacetate microspheres containing trimebutine. | 2002 Oct |
|
TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms [ISRCTN44153243]. | 2002 Oct 16 |
|
Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. | 2003 Apr |
|
Inactivation of cholinesterase induced by chlorpromazine cation radicals. | 2003 Feb |
|
Effect of phenothiazines on protein kinase C- and calcium-dependent activation of peritoneal macrophages. | 2003 Feb |
|
Clinical practice. Vestibular neuritis. | 2003 Mar 13 |
Sample Use Guides
Allergy: the average oral dose is 25 mg taken before retiring; however, 12.5 mg may be taken before meals and on retiring, if necessary. Single 25 mg doses at bedtime or 6.25 to 12.5 mg taken three times daily will usually suffice. After initiation of treatment in children or adults, dosage should be adjusted to the smallest amount adequate to relieve symptoms. The administration of promethazine HCI in 25 mg doses will control minor transfusion reactions of an allergic nature.
Motion Sickness: the average adult dose is 25 mg taken twice daily. The initial dose should be taken one-half to one hour before anticipated travel and be repeated 8 to 12 hours later, if necessary. On succeeding days of travel, it is recommended that 25 mg be taken on arising and again before the evening meal. For children, 12.5 to 25 mg, twice daily, may be administered.
Nausea and Vomiting: antiemetics should not be used in vomiting of unknown etiology in children and adolescents. The average effective dose of Promethazine HCL Oral Solution for the active therapy of nausea and vomiting in children or adults is 25 mg. When oral medication cannot be tolerated, the dose should be given parenterally or by rectal suppository. 12.5 to 25 mg doses may be repeated, as necessary, at 4 to 6 hour intervals. For nausea and vomiting in children, the usual dose is 0.5 mg per pound of body weight, and the dose should be adjusted to the age and weight of the patient and the severity of the condition being treated.
For prophylaxis of nausea and vomiting, as during surgery and the postoperative period, the average dose is 25 mg repeated at 4 to 6 hour intervals, as necessary.
Sedation: this product relieves apprehension and induces a quiet sleep from which the patient can be easily aroused. Administration of 12.5 to 25 mg Promethazine HCl Oral Solution by the oral route will provide sedation in children. Adults usually require 25 to 50 mg for nighttime, presurgical, or obstetrical sedation.
Pre- and Postoperative Use: promethazine HCl Oral Solution in 12.5 to 25 mg doses for children and 50 mg doses for adults the night before surgery relieves apprehension and produces a quiet sleep.
For preoperative medication, children require doses of 0.5 mg per pound of body weight in combination with an appropriately reduced dose of narcotic or barbiturate and the appropriate dose of an atropine-like drug.
Usual adult dosage is 50 mg Promethazine HCl Oral Solution with an appropriately reduced dose of narcotic or barbiturate and the required amount of a belladonna alkaloid. Postoperative sedation and adjunctive use with analgesics may be obtained by the administration of 12.5 to 25 mg in children and 25 to 50 mg doses in adults. Promethazine HCL Oral Solution is contraindicated for children under 2 years of age.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
96590-75-9
Created by
admin on Sat Dec 16 08:30:16 GMT 2023 , Edited by admin on Sat Dec 16 08:30:16 GMT 2023
|
PRIMARY | |||
|
71449006
Created by
admin on Sat Dec 16 08:30:16 GMT 2023 , Edited by admin on Sat Dec 16 08:30:16 GMT 2023
|
PRIMARY | |||
|
SUB126766
Created by
admin on Sat Dec 16 08:30:16 GMT 2023 , Edited by admin on Sat Dec 16 08:30:16 GMT 2023
|
PRIMARY | |||
|
100000152986
Created by
admin on Sat Dec 16 08:30:16 GMT 2023 , Edited by admin on Sat Dec 16 08:30:16 GMT 2023
|
PRIMARY | |||
|
27EM8884DE
Created by
admin on Sat Dec 16 08:30:16 GMT 2023 , Edited by admin on Sat Dec 16 08:30:16 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
SUBSTANCE RECORD